这项研究调查了胃蛋白酶水解水母副产品(Rhopilemahispidum和Lobonemasmithii)的多功能生物活性,专注于它们的抗α-葡萄糖苷酶活性,抗炎作用,抗菌性能,和抑制金黄色葡萄球菌生物膜形成的能力。我们的发现揭示了水母蛋白水解物,特别是来自hopilemahispidum,表现出显着的抗α-葡萄糖苷酶活性,超越了众所周知的α-葡萄糖苷酶抑制剂阿卡波糖。此外,我们证明了这些水解产物在抑制鼠巨噬细胞中脂多糖(LPS)诱导的一氧化氮产生方面的抗炎能力.这种效应是剂量依赖性和非细胞毒性的,突出了水解产物在治疗炎症相关疾病方面的潜力。关于抗菌活性,胃蛋白酶水解水母选择性地表现出对金黄色葡萄球菌的有效作用,包括甲氧西林敏感和耐甲氧西林菌株。对于金黄色葡萄球菌ATCC10832,该活性在25μg/mL的最小抑制浓度(MIC)下是明显的,而对于其他革兰氏阳性菌株观察到适度的效果。水解产物有效地延迟细菌生长的剂量依赖性,建议使用它们作为对抗细菌感染的替代药物。最值得注意的是,胃蛋白酶水解的水母对金黄色葡萄球菌显示出明显的抗生物膜活性。Rhopilemahispidum的伞形切片水解物特别有效,通过下调icaA基因减少生物膜的形成,对生物膜的发展至关重要。此外,水解产物调节了agrA基因的表达,金黄色葡萄球菌发病机制的关键调节因子。总之,胃蛋白酶水解水母蛋白水解产物表现出有希望的多功能生物活性,包括抗糖尿病药,抗炎,抗菌,和抗生物膜特性。这些发现表明了它们在制药和营养食品领域的潜在应用。特别是在管理糖尿病风险方面,炎症,细菌感染,和对抗金黄色葡萄球菌的生物膜相关致病性。
This study investigates the multifunctional bioactivities of pepsin-hydrolyzed jellyfish by-products (Rhopilema hispidum and Lobonema smithii), focusing on their anti-α-glucosidase activity, anti-inflammatory effects, anti-bacterial properties, and ability to inhibit biofilm formation of Staphylococcus aureus. Our findings revealed that jellyfish protein
hydrolysates, particularly from Rhopilema hispidum, exhibit significant anti-α-glucosidase activity, surpassing the well-known α-glucosidase inhibitor Acarbose. Furthermore, we demonstrated the anti-inflammatory capabilities of these
hydrolysates in suppressing lipopolysaccharide (LPS)-induced nitric oxide production in murine macrophage cells. This effect was dose-dependent and non-cytotoxic, highlighting the hydrolysate potential in treating inflammation-related conditions. Regarding anti-bacterial activity, pepsin-hydrolyzed jellyfish selectively exhibited a potent effect against S. aureus, including Methicillin-susceptible and Methicillin-resistant strains. This activity was evident at minimum inhibitory concentrations (MIC) of 25 μg/mL for S. aureus ATCC10832, while a modest effect was observed against other Gram-positive strains. The
hydrolysates effectively delayed bacterial growth dose-dependently, suggesting their use as alternative agents against bacterial infections. Most notably, pepsin-hydrolyzed jellyfish showed significant anti-biofilm activity against S. aureus. The umbrella section hydrolysate of Rhopilema hispidum was particularly effective, reducing biofilm formation through downregulating the icaA gene, crucial for biofilm development. Furthermore, the
hydrolysates modulated the expression of the agrA gene, a key regulator in the pathogenesis of S. aureus. In conclusion, pepsin-hydrolyzed jellyfish protein
hydrolysates exhibit promising multifunctional bioactivities, including anti-diabetic, anti-inflammatory, antibacterial, and anti-biofilm properties. These findings suggest their potential application in pharmaceutical and nutraceutical fields, particularly in managing diabetic risks, inflammation, bacterial infections, and combating the biofilm-associated pathogenicity of S. aureus.